#### NICHD Strategic Plan Responding to Stakeholder Feedback

Diana W. Bianchi Director, NICHD June 11, 2019



Eunice Kennedy Shriver National Institute of Child Health and Human Development



#### **NICHD Strategic Planning**



# Goals

- Identify where NICHD lead (priorities)
- Identify where NICHD partner and collaborat
- Inform future investments in research, training, and infrastructure





### **Request for Information (NOT-HD-18-031)**

- 924 total comments
- Many comments touched on multiple themes/scientific areas
- RFI Summary report is now available: <u>https://www.nichd.nih.gov/about/org/strategicplan</u>

#### **Strategic Plan Themes Proposed in the RFI**



- 1. Understanding Early Human Development
- 2. Setting the Foundation for a Herein Pregnancy and Lifelong Weine Contract of the Pregnancy and Lifelong Wein
- 3. Promoting Gynecological, and Reproductive
- 4. Identifyin Optin Optin Optin Optin
  - C calth During the Transition colescence to Adulthood
- 6. Ensuring Safe and Effective Therapeutics and Devices

### **Draft Research Themes**



#### Where We Are Thanks to Stakeholder Participation

- Revising Strategic Plan themes and priorities
- Revisions will reflect synthesized input from many sources
- Final version shared in September 2019
- THANK YOU for all of your input!



### **Cross-Cutting Themes**

- Cross-cutting themes relevant to all research themes and priorities
  - Global health
  - Health disparities
  - Prevention
  - Nutrition
  - Infectious disease
- Final strategic plan document will include an introductory section to explain broad applicability of these cross-cutting themes
  - Cross-cutting themes may not be explicitly stated in each research theme or priority



(This work is licensed under the <u>Creative</u> <u>Commons Attribution-ShareAlike 3.0</u> License.)



#### Evolution of the Strategic Plan in Response to Stakeholder Feedback

#### **Developmental Biology and Animal Models**

- Increased emphasis on a variety of model systems to understand typical developmental processes
- Expanded from single cell focus and encompassed broader view of genes and gene regulatory networks



# Neurodevelopment and Intellectual & Developmental Disabilities

- Included focus on typical and atypical neurodevelopment from the earliest developmental stages
- Incorporated individuals with intellectual and developmental disabilities throughout the plan, from early human development to transition to adult care and inclusion in development and testing of therapeutics and devices



#### **Reproductive Health**

- Included clearer emphasis on reproductive health as a "window to future health"
- Added investigation of developmental processes that result in abnormalities of the female and male reproductive tracts
- Clarified the need for better characterization and definition of gynecologic and andrologic conditions
- Retained emphasis on fertility and infertility, with a specific role for methods to manage fertility





## **Healthy Pregnancies**

- Incorporated pre-pregnancy factors
- Re-emphasized the priority on placental biology and placental clinical research
- Inclusion of the "fourth trimester"
- Ensured an emphasis on research to address SUID/SIDS and infant mortality





### **Child Development**

- Articulated continued support for studying typical and atypical child development
  - Included social and environmental factors in development of the child and adolescent
  - Life stage transitions emphasized for individuals with intellectual, developmental, and physical disabilities
- Provided a stronger emphasis on the impact of and treatments for the exposure to violence, stress, and trauma







#### **Adolescent Development**

- Clarified areas of emphasis
  - Specific concentration on a better understanding of puberty
  - Incorporated transition of adolescents to the adult health care system, especially those with intellectual, developmental, and physical disabilities and those with chronic conditions





#### Safe and Effective Therapeutics and Devices

- Will continue to focus on development and validation of drugs and devices that affect NICHD's populations
- Conclusions from the federal Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC) will influence our research agenda
- Integrated use of clinical trial and use of "real world" data, such as electronic health records and research registries to measure exposures/responses to therapeutics and devices



